- Rating
- 3(+1)
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 1
Read review
Paper summary
The paper defines a multi-level generative model which includes cell state, and phenotype and batch information, and evaluates how well the representations learned by it perform in downstream analysis.
Critical strengths
S1: Presentation
The paper clarifies it's method, assumptions and it's model clearly. The presentation is good.
S2: Quantitative evaluation of the method
Critical weaknesses
The paper is an interesting read, but needs further work. I encourage the authors to make improvements towards (1) clarifying the role of the identification results and (2) motivating their experimental evaluation, and would consider raising my score if both of these concerns are addressed.
- W1: Irrelevancy of the identification results:
The relevancy of the identification results remains unclear.
- W2: Motivation of the experimental evaluation:
The paper could improve the motivation for the experimental evaluation for downstream tasks.
Questions for authors
- See W1: Do the assumptions made hold in practice?
- See W2: What is the biological relevancy of
recovering donor- and cell-level phenotype variation in unseen donors. - How does the method compare to other hierarchical representation learning frameworks?
- Why does the modeling require a multi-level hierarchy?
2 comments
I thank the authors for their thoughtful response. They have addressed my concerns for W1 and W2.
Detailed response to reviewer TQuM
We thank the reviewer and note the offer to raise the score if W1 and W2 are addressed. We answer both directly here: the full technical treatment of the identifiability scope is in our response to Reviewer 7i31 (Q5) and in the revised Appendix A.6.
W1. Relevance of the identifiability result; do the assumptions hold in practice?
Why it matters. The quantities we interpret biologically are two scalars, td per donor and sn per cell, and a coordinate of a nonlinear latent-variable model has no meaning unless the data determine it: two equally good fits could order the same cells differently, with the ordering an artifact of initialization (Locatello et al., 2019). Theorem 1 says the model’s structure removes this freedom up to a single joint sign flip, with three concrete consequences:
Do the assumptions hold? The donor-level assumptions hold in all four settings: the donor phenotype is observed for every donor and measured independently of the transcriptome. The cell-level assumptions hold in full only in Setting 4 (CAG is an independent PacBio measurement, cell types observed). Settings 1 and 3 have no cell channel, so the donor-level conclusions hold and the cell-level ones reduce to within-type ordering. Setting 2’s maturity score is a function of the counts, so it is not an independent proxy and we do not claim the cell-level conclusions there. We have stated these three roles in the revised Appendix A.6 (scope-by-setting paragraphs). The full derivations are in our 7i31 Q5 response.
W2. Biological relevance of recovering donor- and cell-level variation in unseen donors; comparison to other hierarchical frameworks; why a multi-level hierarchy.
Unseen donors are both the test and the use. The inferred donor state td^ estimates from expression how far a donor has progressed along a process (development, pathology, disease burden). When a label exists, td^ can differ from it usefully (a donor molecularly ahead of or behind its chronological age or neuropathological stage). When none exists (a new cohort without quantitative neuropathology, a model system with no clinical stage), td^ gives a stage from expression alone. At the cell level, where per-cell phenotypes are rarely measured, sn^ places every cell on the same axis as the donor phenotype, so one can ask which types move first as donors progress and which cells within a donor are ahead.
Why two levels. Information is measured at two levels, and a single-level model discards one. Copying the donor label to every cell is pseudoreplication: hundreds of thousands of cells treated as independent observations of a quantity that varies across tens of donors, with every cell of a donor pushed toward the same value despite real within-donor differences. Summarizing cells into one donor prediction (as scVIP does) leaves no per-cell state, so within-donor biology cannot be inferred. HD makes this concrete: the cause is one number per donor (inherited CAG, summarized with age in CAP), but the damage is cell by cell (somatic CAG expands at different rates in different types, and the spiny projection neurons that expand most are the ones that die, Handsaker et al., 2025). Within one donor an SPN and an oligodendrocyte are at very different disease stages despite sharing a CAP score, and CAP per donor and somatic CAG per cell are distinct measured quantities, so a one-level model must drop one.
Comparison to other frameworks. We benchmark scVIP because it is the hierarchical single-cell model that predicts donor phenotypes, just one of the task in question. The general group-level VAEs in Section 2 (Neural Statistician, ML-VAE, FHVAE, Ladder VAE, NVAE, VDVAE) were built for images or speech and have no count likelihood, phenotype channels, or cell-type model. The single-cell multi-group models (multiGroupVI, scPoli, MrVI) learn per-sample embeddings but predict neither a phenotype nor a scalar cell state. To our knowledge no existing method combines all of a group latent, an instance latent, a generative group-to-instance edge, donor and cell phenotype channels, a count likelihood, semi-supervised cell types, and an identifiability result, which is the gap scPACE fills.